Sign up Australia
Proactive Investors - Run By Investors For Investors

Cann Group has funding options on the table for medical cannabis

The halt will remain in place until Monday 4th December 2017.
Cann Group has funding options on the table for medical cannabis
The company's shares are in pre-open

Cann Group Ltd (ASX:CAN) has been one of the leading medical cannabis focused stocks on the ASX over the past year, making a near 400% gain to $3.00.

Cann is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia.

Recently the company was granted a licence to import and/or export cannabis genetics and medicinal cannabis products by the Australian Government Department of Health, through the Office of Drug Control (ODC).

As a holder of this licence, the Company can now apply for a permit to export raw cannabis material and cannabis oil for analytical testing.

To continue the next steps, Cann is heading to market with a capital raising in the form of a placement to institutional, sophisticated and other professional investors.

A share purchase plan will also be offered.

The halt will remain in place until the opening of trade on Monday 4th December 2017, or earlier if an announcement is made to the market.

View full CAN profile View Profile

Cann Group Ltd Timeline

Related Articles

March 01 2018
The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,
DNA sequence
The cell therapy specialist also reported there had been industry interest around its main programmes
man on a ventilator
January 25 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use